Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in active peripheral spondyloarthritis
NCT05206591Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Aug 2022
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of secukinumab in peripheral spondyloarthritis (pSpA), sponsored by Novartis. Planned start Aug 2022; status: withdrawn.
02
Drugs
secukinumab
03
Conditions
peripheral spondyloarthritis (pSpA)
Beyond the preview
Go deeper on NCT05206591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206591.